Aberrant DNA methylation in ovarian cancer: Is there an epigenetic predisposition to drug response?

Susan H. Wei, Robert Brown, Tim H.M. Huang

Research output: Contribution to journalArticlepeer-review

32 Scopus citations

Abstract

Epigenetic regulation of gene expression has been observed in a variety of tumor types. We have used microarray technology to evaluate the predisposition of drug response by aberrant methylation in ovarian cancer. Results indicate that loss of gene activity due to hypermethylation potentially confers a predisposition in certain cancer types and is an early event in disease progression. Methylation profiles of ovarian cancer might be useful for early cancer detection and prediction of chemotherapy outcome in a clinical context.

Original languageEnglish (US)
Pages (from-to)243-250
Number of pages8
JournalAnnals of the New York Academy of Sciences
Volume983
DOIs
StatePublished - Mar 2003
Externally publishedYes

Keywords

  • And mismatch repair
  • Chemotherapy
  • Cisplatin
  • DNA methylation
  • Drug-resistance
  • High-throughput
  • Microarray

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science

Fingerprint Dive into the research topics of 'Aberrant DNA methylation in ovarian cancer: Is there an epigenetic predisposition to drug response?'. Together they form a unique fingerprint.

Cite this